We still have no “silver bullet” against myeloma—a single drug that will cure every patient every time. What is emerging instead is a new drug class, the monoclonal antibody. In this video, Dr. Joseph Mikhael suggests that, in the face of such a heterogeneous disease, more options mean more hope for patients.
Read the transcript | ow.ly/yUNoR
Dr. Joseph R. Mikhael is a hematologist/oncologist at the Mayo Clinc in Arizona, researching and treating multiple myeloma and related cancers.
View more programs featuring Dr. Mikhael | ow.ly/yUNt2
Get email alerts | ow.ly/yUNBO
Loading more stuff…
Hmm…it looks like things are taking a while to load. Try again?